drugset / Trial / NCT02712008

Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema

NCT02712008

Phase 2 Completed 302 enrolled Regeneron Pharmaceuticals Bayer · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of the study was to compare the efficacy of intravitreal (IVT)-administered REGN910-3 compared to intravitreal aflibercept injection (IAI) in improving best corrected visual acuity (BCVA) in participants with diabetic macular edema (DME).

Timeline

Start
2016-03-02
Primary completion
2017-07-10
Completion
2017-07-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Aflibercept Protein / enzyme biologic 2 mg Intravitreal
Subject nesvacumab Monoclonal antibody 3 mg Intravitreal
Subject nesvacumab Monoclonal antibody 6 mg Intravitreal